Tuesday, March 5, 2024
Follow us on :

Arbor Biotechnologies Appoints Industry Veteran R. Nolan Townsend to Board of Directors

CAMBRIDGE, Mass., Nov. 07, 2023 (GLOBE NEWSWIRE) -- Arbor Biotechnologies®, a biotechnology company discovering and developing the next generation of genetic medicines, today announced the appointment of R. Nolan Townsend to the Company's Board of Directors. Mr. Townsend is the Chief Executive Officer of LEXEO Therapeutics, a clinical stage gene therapy company advancing candidates for genetically defined cardiovascular diseases and a genetically defined sub-group of Alzheimer's disease.

"We're honored to have Nolan join our board and partner with our leadership team at this pivotal time," said Devyn Smith, Ph.D., CEO of Arbor. "His knowledge of the genetic medicine field and decade of leadership across key functions in a global healthcare organization will be invaluable as we work toward our goal of obtaining 3 clinical filings in the next three years and advancing the first non-CAS9 nuclease into in vivo testing in humans."

Prior to LEXEO, Mr. Townsend spent over a decade with Pfizer, most recently as President, Pfizer Rare Disease for the North America region and President, Pfizer ...

Full story available on

Disclaimer: The views, recommendations, and opinions expressed in this content belong solely to the third-party experts. This site was not involved in the writing and production of this article.

Disclaimer Press Release Banner